Leading Biopharma Company Adopts Medidata Technology to Bring Operational Efficiencies and Greater Speed to Innovative Clinical Study on Metabolic Disorders
Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that TWi Biotechnology, Inc. has selected the Medidata Clinical Cloud® to enhance the speed, quality and productivity of its novel clinical study on metabolic disorders.
TWi Biotechnology, Inc., a fully owned subsidiary of TWi Pharmaceuticals, Inc. based in Taipei, Taiwan, specializes in the development of innovative new drugs for unmet medical needs, especially in the diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. To optimize a Phase II study on metabolic disorders, TWi Biotechnology is implementing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®).
Read the full release here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.